Nerve regeneration: Grafts, conduits, and strategies

Textbook of Reconstructive Urologic Surgery

Volumn , Issue , 2008, Pages 781-789

  Burnett, Arthur L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72849126477     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (60)

1. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998; 160: 2418-24.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65.
3. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138-44.
4. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293: 2648-53.
5. Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology 2003; 61: 491-7.
6. Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol 2006; 50: 711-18.
7. Dellon AL, Mackinnon SE. Basic scientific and clinical applications of peripheral nerve regeneration. Surg Annu 1988; 20: 59-100.
8. Sunderland S. Nerve grafting and related methods of nerve repair. In: Sunderland S, ed. Nerve injuries and their repair: a critical apprasial. New York: Churchill Livingstone, 1991: 467-97.
9. Evans GR. Peripheral nerve injury: a review and approach to tissue engineered constructs. Anat Rec 2001; 263: 396-404.
10. Kury P, Stoll G, Muller HW. Molecular mechanisms of cellular interactions in peripheral nerve regeneration. Curr Opin Neurol 2001; 14: 635-9.
11. Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145: 380-3.
12. Burgers JK, Nelson RJ, Quinlan DM, Walsh PC. Nerve growth factor, nerve grafts and amniotic membrane grafts restore erectile function in rats. J Urol 1991; 146: 463-8.
13. Ball RA, Lipton SA, Dreyer EB, Richie JP, Vickers MA. Entubulization repair in severed cavernous nerves in the rat resulting in return of erectile function. J Urol 1992; 148: 211-15.
14. Walsh PC. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology 2001; 57: 1020-4.
15. Kim ED, Scardino PT, Hampel O et al. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol 1999; 161: 188-92.
16. Kim ED, Nath R, Kadmon D et al. Bilateral nerve graft during radical retropubic prostatectomy: 1-year follow-up. J Urol 2001; 165: 1950-6.
17. Kim ED, Nath R, Slawin KM et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 2001; 58: 983-7.
18. Scardino PT, Kim ED. Rationale for and results of nerve grafting during radical prostatectomy. Urology 2001; 57: 1016-19.
19. Chang DW, Wood CG, Kroll SS, Youssef AA, Babaian RJ. Cavernous nerve reconstruction to preserve erectile function following non-nerve-sparing radical retropubic prostatectomy: a prospective study. Plast Reconstr Surg 2003; 111: 1174-81.
20. Anastasiadis AG, Benson MC, Rosenwasser MP et al. Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer Prostatic Dis 2003; 6: 56-60.
21. Nelson BA, Chang SS, Cookson MS, Smith JA Jr. Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. Urology 2006; 67: 789-92.
22. Kim ED, Scadino PT, Kadmon D, Slawin K, Nath RK. Interposition sural nerve grafting during radical retropubic prostatectomy. Urology 2001; 57: 211-16.
23. Kim ED, Seo JT. Minimally invasive technique for sural nerve harvesting: technical description and follow-up. Urology 2001; 57: 921-4.
24. Canto EI, Nath RK, Slawin KM. Cavermap-assisted sural neve interposition graft during radical prostatectomy. Urol Clin North Am 2001; 28: 839-48.
25. Holzbeierlein J, Peterson M, Smith JA Jr. Variability of results of cavernous nerve stimulation during radical prostatectomy. J Urol 2001; 165: 108-10.
26. Turk IA, Deger S, Morgan WR et al. Sural nerve graft during laparoscopic radical prostatectomy. Initial experience. Urol Oncol 2002; 7: 191-4.
27. Porpiglia F, Ragni F, Terrone C et al. Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency? BJU Int 2005; 95: 1267-71.
28. Kaouk JH, Desai MM, Abreu SC, Papay F, Gill IS. Robotic assisted laparoscopic sural nerve grafting during radical prostatectomy: initial experience. J Urol 2003; 170: 909-12.
29. Srougi M, Pereira D, Dall'Oglio M. Sexual rehabilitation after radical retropubic prostatectomy: new technique using ilio-inguinal nerve graft. Int Braz J Urol 2002; 28: 446-50.
30. Walsh PC, Epstein JI, Lowe FC. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 1987; 138: 823-7.
31. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991; 145: 998-1002.
32. Michl UH, Friedrich MG, Graefen M et al. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol 2006; 176: 227-31.
33. Takenaka A, Murakami G, Matsubara A, Han SH, Fujisawa M. Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. Urology 2005; 65: 136-42.
34. Takenaka A, Kawada M, Murakami G et al. Interindividual variation in distribution of extramural ganglion cells in the male pelvis: a semi-quantitative and immunohistochemical study concerning nerve-sparing pelvic surgery. Eur Urol 2005; 48: 46-52.
35. Costello AJ, Brooks M, Cole OJ. Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int 2004; 94: 1071-6.
36. Secin FP, Koppie TM, Patel M et al. Determinants of success of bilateral cavernous nerve interposition grafting during radical retropubic prostatectomy. J Urol 2006; 175: 423-4 (abst).
37. Burnett AL. Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction. J Urol 2003; 170: S31-4.
38. Parsons JK, Marschke P, Maples P, Walsh PC. Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. Urology 2004; 64: 987-90.
39. Deliveliotis C, Delis A, Papatsoris A, Antoniou N, Varkarakis IM. Local steroid application during nerve-sparing radical retropubic prostatectomy. BJU Int 2005; 96: 533-5.
40. Sezen SF, Hoke, A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073-4.
41. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 2004; 171: 495-500.
42. Hayashi N, Minor TX, Carrion R et al. The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J Urol 2006; 176: 824-9.
43. Valentine H, Chen Y, Guo H et al. Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur Urol 2007; 51: 1724-31.
44. Hamilton GS, Steiner JP. Immunophilins: beyond immunosuppression. J Med Chem 1998; 41: 5119-43.
45. Gold BG, Villafranca JE. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 2003; 3: 1368-75.
46. Klettner A, Herdegen T. FK506 and its analogs - therapeutic potential for neurological disorders. Curr Drug Targets CNS Neurol Disord 2003; 2: 153-62.
47. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 2003; 3: 1376-82.
48. Sezen SF, Blackshaw S, Steiner JP, Burnett AL. FK506 binding protein 12 is expressed in rat penile innervation and upregu- lated after cavernous nerve injury. Int J Impot Res 2002; 14: 506-12.
49. Tanaka K, Yoshioka M, Miyazaki I, Fujita N, Ogawa N. GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. Neurosci Lett 2002; 321: 45-8.
50. Tanaka K, Fujita N, Yoshioka M, Ogawa N. Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brian Res 2001; 889: 225-8.
51. Burnett AL. General use of animal models for investigation of the physiology of erection. Int J Impot Res 2001; 13: 135-9.
52. Lue, TF, Gleason CA, Brock GB, Carroll PR, Tanagho EA. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol 1995; 154: 1426-8.
53. Stief CG, Weller E, Noack T et al. Functional electromyostimulation of the corpus cavernosum penis - preliminary results of a novel therapeutic option for erectile dysfunction. World J Urol 1995; 13: 243-7.
54. Burnett AL, Montorsi F, Briganti A. Intraoperative assessment of an implantable electrode array for cavernous nerve stimulation. J Urol 2006; 175: 421-2 abstr.
55. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413.
56. Apfel SC. Neurotrophic factor therapy - prospects and problems. Clin Chem Lab Med 2001; 39: 351-5.
57. Djakiew D, Pflug BR, Delsite R et al. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 1993; 53: 1416-20.
58. Miknyoczki SJ, Wan W, Chang H et al. The neurotrophin- trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 2002; 8: 1924-31.
59. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Ciol 2001; 21: 8385-97.
60. Burnett AL, Kramer MF, Dalrymple S, Isaacs JT. Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells. Urology 2005; 65: 1003-7.